Home World News FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma

FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma

November 13, 2024

713

FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device